NAMUSCLA

This brand name is authorized in Austria, Estonia, France, Croatia, Ireland, Italy, Lithuania, Poland, United Kingdom

Active ingredients

The drug NAMUSCLA contains one active pharmaceutical ingredient (API):

1 Mexiletine UNII 606D60IS38 - MEXILETINE HYDROCHLORIDE

Mexiletine blocks sodium channels with a stronger potency in situations of excessive burst of action potentials (use-dependent block) and/or prolonged depolarization (voltage-dependent block), as occurring in diseased tissues, rather than on physiological excitability (resting or tonic block). Mexiletine is, therefore, mostly active on muscle fibres subject to repeated discharges (such as skeletal muscles). It improves myotonic symptoms by decreasing muscle stiffness through reduction of the delay of muscle relaxation. Read about Mexiletine

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
NAMUSCLA Hard capsule	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
C01BB02	Mexiletine	C Cardiovascular system → C01 Cardiac therapy → C01B Antiarrhythmics, class I and III → C01BB Antiarrhythmics, class Ib
Discover more medicines within C01BB02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1786552, 1786563, 1786574, 1786585
Country: FR	Base de données publique des médicaments	Identifier(s): 67638864
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 365389
Country: IT	Agenzia del Farmaco	Identifier(s): 047474010, 047474034, 047474046
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1086877, 1086878, 1086879, 1086880
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100416476